share_log

Nantahala Capital Management LLC Has $934,000 Stock Holdings in Acer Therapeutics Inc. (NASDAQ:ACER)

Nantahala Capital Management LLC Has $934,000 Stock Holdings in Acer Therapeutics Inc. (NASDAQ:ACER)

Nantahala Capital Management LLC持有宏碁治療公司(納斯達克股票代碼:ACER)93.4萬美元的股票
Financial News Live ·  2022/12/06 00:33

Nantahala Capital Management LLC reduced its stake in Acer Therapeutics Inc. (NASDAQ:ACER – Get Rating) by 4.7% during the 2nd quarter, Holdings Channel.com reports. The firm owned 741,010 shares of the biopharmaceutical company's stock after selling 36,810 shares during the period. Nantahala Capital Management LLC's holdings in Acer Therapeutics were worth $934,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Holdings Channel.com報道,Nantahala Capital Management LLC在第二季度將其在宏碁治療公司(納斯達克股票代碼:ACER——獲取評級)的股份減少了4.7%。該公司在此期間出售了36,810股股票後,擁有這家生物製藥公司的741,010股股票。截至最近向美國證券交易委員會(SEC)提交文件,Nantahala Capital Management LLC在宏碁Therapeutics的持股價值93.4萬美元。

Several other large investors also recently modified their holdings of the stock. Vanguard Group Inc. boosted its holdings in shares of Acer Therapeutics by 55.5% during the 1st quarter. Vanguard Group Inc. now owns 278,215 shares of the biopharmaceutical company's stock worth $807,000 after buying an additional 99,335 shares during the period. Renaissance Technologies LLC lifted its position in Acer Therapeutics by 216.8% during the second quarter. Renaissance Technologies LLC now owns 69,700 shares of the biopharmaceutical company's stock worth $88,000 after acquiring an additional 47,700 shares during the last quarter. Finally, Copperwynd Financial LLC bought a new stake in shares of Acer Therapeutics during the second quarter worth approximately $29,000. 9.76% of the stock is owned by institutional investors.

其他幾位大型投資者最近也修改了他們對該股的持有量。Vanguard Group Inc. 在第一季度將其持有的宏碁Therapeutics的股票增加了55.5%。Vanguard Group Inc. 在此期間又購買了99,335股股票後,現在擁有這家生物製藥公司的278,215股股票,價值80.7萬美元。Renaissance Technologies LLC在第二季度將其在宏碁治療公司的頭寸提高了216.8%。Renaissance Technologies LLC在上個季度又收購了47,700股股票後,現在擁有這家生物製藥公司的69,700股股票,價值88,000美元。最後,Copperwynd Financial LLC在第二季度購買了Acer Therapeutics的新股份,價值約29,000美元。該股票的9.76%由機構投資者持有。

Get
得到
Acer Therapeutics
宏碁療法
alerts:
警報:

Insider Activity at Acer Therapeutics

宏碁治療的內幕活動

In other news, CEO Chris Schelling acquired 819,672 shares of the stock in a transaction on Tuesday, November 29th. The shares were purchased at an average price of $1.22 per share, for a total transaction of $999,999.84. Following the transaction, the chief executive officer now directly owns 2,712,529 shares of the company's stock, valued at $3,309,285.38. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. 20.20% of the stock is currently owned by corporate insiders.

在其他新聞方面,首席執行官克里斯·謝林在11月29日星期二的一次交易中收購了該股819,672股股票。這些股票以每股1.22美元的平均價格購買,總交易額爲999,999.84美元。交易完成後,首席執行官現在直接擁有該公司2712,529股股票,價值3,309,285.38美元。此次收購是在向美國證券交易委員會提交的文件中披露的,該文件可通過以下方式獲得 美國證券交易委員會網站。20.20% 的股票目前由企業內部人士持有。

Acer Therapeutics Price Performance

宏碁療法的價格表現

Shares of Acer Therapeutics stock traded up $0.04 on Monday, hitting $1.54. The stock had a trading volume of 4,594 shares, compared to its average volume of 203,687. Acer Therapeutics Inc. has a twelve month low of $1.11 and a twelve month high of $3.77. The business's 50 day moving average is $1.27 and its two-hundred day moving average is $1.49.
週一,宏碁治療股價上漲0.04美元,觸及1.54美元。該股的交易量爲4594股,而平均成交量爲203,687股。Acer Therapeutics Inc.創下十二個月低點1.11美元,創下十二個月高點3.77美元。該公司的50天移動平均線爲1.27美元,其200天移動平均線爲1.49美元。

Acer Therapeutics Company Profile

宏碁 Therapeutics 公司簡介

(Get Rating)

(獲取評級)

Acer Therapeutics Inc, a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19.

Acer Therapeutics Inc是一家制藥公司,專注於嚴重罕見和危及生命的疾病療法的收購、開發和商業化。其產品線包括四種臨床階段候選藥物,包括用於治療已確診 III 型膠原突變患者的血管 Ehlers-Danlos 綜合徵的 Edsivo;ACER-001,一種用於治療各種先天代謝缺陷(包括尿素循環障礙和楓糖尿病)的苯丁酸鈉配方;用於治療誘發的血管舒縮症狀的 ACER-801(奧沙奈坦);以及宿主導療法 ACER-2820(依美汀)對抗各種傳染病,包括 COVID-19。

Featured Articles

精選文章

  • Get a free copy of the StockNews.com research report on Acer Therapeutics (ACER)
  • Insiders And Institutions Buy Fastenal, An Aristocrat To Be
  • Is Big Lots the Next Bed Bath & Beyond Disaster in the Making?
  • Is Salesforce Stock a Bargain Down Here?
  • Intel is a Sleeping Giant Ready to Awaken
  • Why CSL Ltd Stock Could Be Worth a Look
  • 免費獲取 StockNews.com 關於宏碁 Therapeutics(ACER)的研究報告的副本
  • 業內人士和機構購買 Fastenal,即將成爲貴族
  • Big Lots 是下一個 Bed Bath & Beyond 災難正在形成的嗎?
  • Salesforce 的股票在這裏便宜嗎?
  • 英特爾是準備覺醒的沉睡巨人
  • 爲甚麼 CSL Ltd 的股票值得一看

Want to see what other hedge funds are holding ACER? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Acer Therapeutics Inc. (NASDAQ:ACER – Get Rating).

想看看還有哪些對沖基金持有宏碁嗎? 訪問HoldingSchannel.com,獲取宏碁治療公司(納斯達克股票代碼:ACER — 獲取評級)的最新13F文件和內幕交易。

Receive News & Ratings for Acer Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acer Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

接收 Acer Therapeutics 每日的新聞和評級 -在下面輸入您的電子郵件地址,通過Marketbeat.com的免費每日電子郵件時事通訊接收Acer Therapeutics及相關公司的最新新聞和分析師評級的簡明每日摘要。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論